# US 2017/0362596 A1 · Methods and means of generating il-17 associated antitumor effector cells by inhibition of nr2f6 inhibition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362596 A1
- Document ID: US20170362596A1
- Status: Published application
- Kind: A1
- Application number: 15/431,681
- Filed: 2017-02-13
- Published: 2017-12-21
- Earliest claimed: 2016-02-11
- Assignees: Regen Biopharma, Inc.
- Applicants: Regen Biopharma, Inc
- Inventors: David KOOS; Thomas ICHIM; Santosh KESARI
- Web page: https://patentgrep.com/patent/US20170362596A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/17: Monocytes; Macrophages
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/32: of the sugar
- C12N 2310/3341: 5-Methylcytosine
- C12N 2501/60: Transcription factors
- C12N 2502/1157: Monocytes, macrophages
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are means, methods, and compositions of matter useful for generation of cancer inhibitory effector cells producing interleukin-17 (IL-17). In one embodiment a cellular population is obtained, said cellular population is exposed to agents capable of inhibiting NR2F6, whereby said inhibition of NR2F6 results in upregulation of IL-17 production, said upregulation of IL-17 production associated with acquisition of anti-tumor activity.

## Claims

### Claim 1

A cellular population capable of inhibiting cancer, said cellular population modulated to express lower levels of NR2F6 as compared to non-manipulated cellular population, wherein said lower level of NR2F6 is associated with augmentation of IL-17 production, wherein said IL-17 production is associated with reduction of tumor activity.

### Claim 2 (depends on 1)

The cellular population of claim 1, wherein said cellular population is selected from a group comprising of: a) T cells; b) NK cells; c) gamma delta T cells; and NKT cells.

### Claim 3 (depends on 1)

The cellular population of claim 1, wherein said inhibition of NR2F6 is achieved by means selected from a group comprising of: a) antisense oligonucleotides; b) induction of RNA interference; c) small molecule inhibitors; d) aptamers; e) gene-editing; f) ribozymes; and g) decoy oligonucleotides.

### Claim 4 (depends on 3)

The cellular population of claim 3, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 5 (depends on 3)

The cellular population of claim 3, wherein at least one nucleoside comprises a modified sugar.

### Claim 6 (depends on 3)

The cellular population of claim 3, wherein at least one said nucleobase is a modified nucleobase.

### Claim 7 (depends on 6)

The cellular population of claim 6, wherein the modified nucleobase is a 5-methylcytosine.

### Claim 8 (depends on 3)

The cellular population of claim 3, wherein said RNA interference is induced by administration of a compound selected from a group comprising of: a) single-stranded small interfering molecules (ss-siRNA); b) short interfering RNA (siRNA); c) miRNA; and d) short hairpin RNA (shRNA).

### Claim 9 (depends on 8)

The cellular population of claim 8, wherein the sequence of said ss-siRNA molecule is sufficiently complementary to the human NR2F6 mRNA sequence to direct target-specific RNAi and wherein the 5′ nucleotide is 5′ phosphorylated or is capable of being 5′ phosphorylated in situ or in vivo.

### Claim 10 (depends on 9)

The cellular population of claim 9, wherein said ss-siRNA is sufficiently complementary to a target NR2F6 mRNA, said target NR2F6 mRNA specifying the amino acid sequence of said NR2F6 protein.

### Claim 11 (depends on 8)

The cellular population of claim 8, wherein said siRNA comprising a sense strand and an antisense strand, wherein the antisense strand has a sequence sufficiently complementary to a NR2F6 target mRNA sequence to direct target-specific RNAi and wherein the sense strand or antisense strand is modified by the substitution of at least one internal nucleotide with a modified nucleotide, such that in vivo stability is enhanced as compared to a corresponding unmodified siRNA or such that the target efficiency is enhanced compared to a corresponding unmodified siRNA.

### Claim 12 (depends on 11)

The cellular population of claim 11, wherein the modified nucleotide is selected from the group consisting of (a) a sugar-modified nucleotide, (b) a nucleobase-modified nucleotide, (c) a 2′-deoxy ribonucleotide and is present within the sense strand (d) a 2′-fluoro modified ribonucleotide, (e) a modified nucleotide is selected from the group consisting of a 2′-fluoro, 2′-amino and 2′-thio modified ribonucleotide, (f) modified nucleotides which are a 2′-fluoro modified ribonucleotide (e.g., 2′-fluoro uridine or 2′-fluoro cytidine) and a 2′-deoxy ribonucleotide (e.g., 2′-deoxy adenosine or 2′-deoxy guanosine), (g) a modified nucleotide is selected from the group consisting of 2′-fluoro-cytidine, 2′-fluoro-uridine, 2′-fluoro-adenosine, 2′-fluoro-guanosine, 2′-amino-cytidine, 2′-amino-uridine, 2′-amino-adenosine, 2′-amino-guanosine and 2′-amino-butyryl-pyrene-uridine, (h) modified nucleotide is selected from the group consisting of 5-bromo-uridine, 5-iodo-uridine, 5-methyl-cytidine, ribo-thymidine, 2-aminopurine, 5-fluoro-cytidine, and 5-fluoro-uridine, 2,6-diaminopurine, 4-thio-uridine; and 5-amino-allyl-uridine, or (i) a backbone-modified nucleotide. (e.g., contains a phosphorothioate group).

### Claim 13 (depends on 11)

The cellular population of claim 11, wherein one strand of said siRNA is comprised of the nucleotide sequence: SEQ ID NO 1: 5′-GAT CCG CAT TAC GGT GTC TTC ACC TTC AAG AGA GGT GAA GAC ACC GTA ATG CTT TTT TCT AGA G-3′

### Claim 14 (depends on 11)

The cellular population of claim 11, wherein one strand of said siRNA is comprised of the nucleotide sequence: SEQ ID NO 2: 5′-GAT CCG CCT CTG GAC ACG TAA CCT ATT CAA GAG ATA GGT TAC GTG TCC AGA GGT TTT TTC TAG AG-3′.

### Claim 15

A method of generating a tumor killing population of cells comprising admixing NR2F6 inhibited T cells with monocytes, allowing said T cells to induce monocyte activation and said monocytes to feedback activatory signals to said T cells.

### Claim 16 (depends on 15)

The method of claim 15, wherein said monocytes are type 1 monocytes.

### Claim 17 (depends on 15)

The method of claim 15, wherein said monocyte activatory signal produced by said T cells is IL-17.

### Claim 18 (depends on 15)

The method of claim 15, wherein said T cell activatory signal produced by said monocyte is IL-12.
